Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "Blood"

Add to list
The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1

Catherine L Carmichael, Jueqiong Wang, Thao Nguyen, Oluseyi Kolawole, Aissa Benyoucef, Charlotte De Mazière, Anna Milne, Sona Samuel, Kevin Robert Gillinder, Soroor Hediyeh-zadeh, et al.

(2020) BLOOD.
Add to list
- Journal Article
- A1
The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation

Sylvie Taveirne (UGent) , Sigrid Wahlen (UGent) , Wouter Van Loocke (UGent) , Laura Kiekens (UGent) , Eva Persyn (UGent) , Els Van Ammel (UGent) , Katrien De Mulder (UGent) , Juliette Roels (UGent) , Laurentijn Tilleman (UGent) , Marc Aumercier, et al.

(2020) BLOOD.
Add to list
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.

Renate De Smedt (UGent) , Julie Morscio (UGent) , Lindy Reunes (UGent) , Juliette Roels (UGent) , V Bardelli, Béatrice Lintermans (UGent) , Wouter Van Loocke (UGent) , André Pedro Pinto De Almeida (UGent) , LC Cheung, RS Kotecha, et al.

(2020) BLOOD. 135(19). p.1685-1695
Add to list
Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.

Barbara De Moerloose (UGent) , R De Smedt, J Morscio, L Reunes, J Roels, V Bardelli, B Lintermans, W Van Loocke, A Almeida, J T Barata, et al.

(2020) BLOOD.
Add to list
Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival

Willem Daneels (UGent) , Michael Rosskamp, Gilles Macq, Estabraq Ismael Saadoon, Anke De Geyndt, Fritz Offner (UGent) and Helene A Poirel

(2019) BLOOD. 134(suppl. 1). p.2894-2894
Add to list
- Miscellaneous
Priority lane to cDC1 open for IRF8⁺ progenitors

Martin Guilliams (UGent) and Charlotte Scott (UGent)

(2019) BLOOD. 133(17). p.1795-1797
Add to list
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

Sara El Ashkar, Juerg Schwaller, Tim Pieters (UGent) , Steven Goossens (UGent) , Jonas Demeulemeester, Frauke Christ, Siska Van Belle, Sabine Juge, Nancy Boeckx, Alan Engelman, et al.

(2018) BLOOD. 131(1). p.95-107
Add to list
- Conference Paper
- C3
Argx-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1/2 clinical trial

Martine Bagot, Marie Maerevoet, Pier Luigi Zinzani, Fritz Offner (UGent) , Franck Morschhauser, Jean-Marie Michot, Vincent Ribrag, Maxime Battistella, Helene Moins, Angelica Calleri, et al.

(2018) BLOOD. 132(suppl. 1).
Add to list
- Conference Paper
- C3
CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial

Martin Hutchings, Gloria Iacoboni, Franck Morschhauser, Fritz Offner (UGent) , Anna Sureda, Gilles Andre Salles, Carmelo Carlo-Stella, Joaquin Martinez Lopez, Denise Thomas, Peter N Morcos, et al.

(2018) BLOOD. 132(suppl. 1).
Add to list
- Conference Paper
- C3
AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner (UGent) , Adriana Scheliga, Grzegorz S Nowakowski, et al.

(2018) BLOOD. 132(suppl. 1).

Academic Bibliography

The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1

The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation

Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.

Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.

Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival

Priority lane to cDC1 open for IRF8⁺ progenitors

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

Argx-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1/2 clinical trial

CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial

AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

Contents

Support

Contact